NCT07567716

Brief Summary

Prospectively collect the pathological records of ESCC patients, and analyse the infiltration pattern of ESCC.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
8mo left

Started Oct 2025

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress48%
Oct 2025Dec 2026

Study Start

First participant enrolled

October 1, 2025

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2026

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

April 22, 2026

Completed
13 days until next milestone

First Posted

Study publicly available on registry

May 5, 2026

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Expected
Last Updated

May 5, 2026

Status Verified

April 1, 2026

Enrollment Period

6 months

First QC Date

April 22, 2026

Last Update Submit

April 30, 2026

Conditions

Keywords

esophageal squamous cell carcinomainfiltration patternprognosisresection margin

Outcome Measures

Primary Outcomes (1)

  • Infiltration pattern

    Direct infiltration length of ESCC beyond macroscopic margin and multiple lesions of ESCC.

    Postoperatively, based on the pathological results of the specimen. Usually, the results will be reported within one month after surgery.

Study Arms (1)

esophagectomy group

Receive esophagectomy for treatment

Other: EsophagectomyProcedure: Esophagectomy

Interventions

Esophagectomy by McKeown method

esophagectomy group

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with c/ycT2-3 esophageal squamous cell carcinoma (ESCC) who underwent McKeown esophagectomy.

You may qualify if:

  • cervical or thoracic ESCC
  • received esophagectomy
  • preoperative stage T2-3
  • no viable multiple lesions
  • received McKeown esophagectomy

You may not qualify if:

  • Incomplete clinical materials

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shanghai Chest Hospital

Shanghai, 20030, China

Location

Related Publications (1)

  • MA G W, RONG T H, WU Q L, et al. Giant pathologic section in the study of optimal length of surgical resection for esophageal carcinoma [J]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2003, 25(5): 472-474.

    BACKGROUND

MeSH Terms

Conditions

Esophageal Squamous Cell CarcinomaNeoplasmsMargins of Excision

Interventions

Esophagectomy

Condition Hierarchy (Ancestors)

Carcinoma, Squamous CellCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasms, Squamous CellEsophageal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteHead and Neck NeoplasmsDigestive System DiseasesEsophageal DiseasesGastrointestinal DiseasesMorphological and Microscopic FindingsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Digestive System Surgical ProceduresSurgical Procedures, Operative

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof.

Study Record Dates

First Submitted

April 22, 2026

First Posted

May 5, 2026

Study Start

October 1, 2025

Primary Completion

April 1, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

May 5, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations